Please enter exact key words
AVAILABLE PROJECTS
Program Indication Target Discovery Preclinical PhaseⅠ PhaseⅡ PhaseⅢ
Antibody Therapy
Antibody Product Portfolio Cancer Multiple targets
ANTIGN-109 Cancer GnRHR
ANTICA-201 Cancer CA215
CD3XCD20 bsAb Lymphomas CD3; CD20
Anti-MUC1-Ab Solid tumor MUC1
CD3xBCMA-bsAb Multiple myeloma CD3; BCMA
Anti-CD40-7409 Cancer CD40
BioLink018 Non-Hodgkin lymphoma CD79B
Anti-CD137-6051 Cancer CD137
IGY-110 Covid-19 Spike proteins
Anti-LAG3 mAb Cancer LAG3
OX40-Ab Cancer OX40
A1801 ADC Breast cancer; Melanoma GPNMB
PMB-104 Asthma Immunoglobulin E
PMB-107 Solid tumor GARP/LAP-TGFβ1 complex
PBI-108 Solid tumor PD-1 and Siglec-15
PMB-109 Asthma TSLP
PMB-131 IgA nephropathy MASP-2
PBI-203 Solid tumor PD-L1 and VEGF
PBI-204 Sepsis Adrenomedullin
PBI-205 Solid tumor PD-1 and PD-L1
PMB-211 Fibrosis CTGF
Recombinant Protein Therapy
P75NEURO Neurological diseases p75NTR (NGFR)
P11 Type 2 diabetes GLP-1 receptor
Angiocidin Acute myeloid leukemia Death receptor 6
TT-173 Surgical bleeding and trauma
BioLink001 Solid tumor IL-15
Oncolytic Virotherapy
RV-scFv-PDL1 Cancer PD-L1
OV-FV-01 Cancer Confidential
BS001 Cancer
Small Molecules
Polyoxygenated Cyclohexene Compound 4 Pain Nav1.7
PPM-100 Cancer IKZF1/3
Fascin Inhibitor Cancer Fascin
Resveratrol (Micellar) Alzheimer’s disease SIRT1
NMMHC IIA Inhibitors Thrombosis NMMHC IIA
VISTA Agonist Psoriasis VISTA
Berbamine Analogues (+)ssRNA virus infections TRPML
Intravenous Anesthetics Anesthesia GABA(A) receptor
Water-soluble Taxanes Cancer Tubulin
FHND41 NSCLC EGFR
BioLink1006 Metastatic cancer EGFR
BioLink2018 B-cell lymphomas BTK
BioLink2020 Solid tumor FGFR1-3
BioLink2022 Heart failure PDE9
BioLink2024 Inflammatory diseases NLRP3
FHND91 Multiple myeloma Proteasome
FHND71 Solid tumor RET
Cell Therapy
Double Negative T Cells Acute myelocytic leukemia Multi-target
Anti-BCMA CAR-T Cell Multiple myeloma BCMA
Anti-GPRC5D CAR T-cell Multiple myeloma GPRC5D
Gene Therapy
RNA4TNBC Triple-negative breast cancer MIR34A; MIR21
ABOUT US

Protheragen’s business is growing rapidly after founded in New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen Inc.